Lee Megan, Reed Aimee, Estill Charles, Izume Satoko, Dong Jing, Jin Ling
Department of Biomedical Sciences, College of Veterinary Medicine, Oregon State University, Corvallis, OR 97331, United States.
Department of Clinical Sciences, College of Veterinary Medicine, Oregon State University, Corvallis, OR 97331, United States.
Vet Microbiol. 2015 Sep 30;179(3-4):228-32. doi: 10.1016/j.vetmic.2015.06.009. Epub 2015 Jun 23.
Although modified-live multivalent vaccines, such as PregGuard GOLD and Bovi-Shield Gold, have been used routinely in both beef and dairy cattle in the US, abortion and respiratory diseases still occasionally occur following vaccination. To determine whether the antibody induced by the multivalent vaccine can recognize BHV-1 isolates from aborted animals, BHV-1 antibody titer was evaluated with two isolates from abortion cases and two vaccine BHV-1 viruses. Cattle serum was collected from a dairy herd that was vaccinated annually with Bovi-Shield Gold 5 vaccine. Among the 28 cattle tested, no statistical significant difference in serum neutralization titer was observed when test virus was either vaccine virus or clinical isolates. It suggests that the BHV-1 antibody from the vaccinated cattle can recognize both the vaccine virus and clinical isolates. However, it is noticed that cows at 5 years old or older had a significantly lower BHV-1 antibody titer on average than the average of SN titer in 3 year-old cows. Similarly, cows at 5 years or older had a significantly lower BVDV antibody titer than cows at about 2 years of age. In addition, cattle vaccinated within 0-2 months had a significantly higher BHV-1 titer than those that received vaccination 6 months or greater prior to titer measurement. In contrast, cattle that received a vaccination 6 months prior had a significantly higher anti-BVDV antibody titer than those vaccinated within 1-2 months. The BVDV antibody titers remained relatively unchanged between 6 months and 1 year post-vaccination. Our study suggests little antigenic variation exists between BHV-1 disease isolates and BHV-1 of the multivalent vaccines. In addition, BHV-1 antibody titer is relatively lower at 6 months post vaccination in those tested animals. However, the BVDV antibody titer remained relatively high after 6 months from time of vaccination.
尽管改良活多价疫苗,如PregGuard GOLD和Bovi-Shield Gold,已在美国的肉牛和奶牛中常规使用,但接种疫苗后仍偶尔会出现流产和呼吸道疾病。为了确定多价疫苗诱导的抗体是否能识别流产动物的牛疱疹病毒1型(BHV-1)分离株,用两株来自流产病例的分离株和两种疫苗BHV-1病毒评估了BHV-1抗体滴度。从每年接种Bovi-Shield Gold 5疫苗的奶牛群中采集牛血清。在测试的28头牛中,当测试病毒为疫苗病毒或临床分离株时,血清中和滴度没有观察到统计学上的显著差异。这表明接种疫苗的牛的BHV-1抗体既能识别疫苗病毒,也能识别临床分离株。然而,注意到5岁及以上的奶牛平均BHV-1抗体滴度明显低于3岁奶牛的血清中和滴度平均值。同样,5岁及以上的奶牛牛病毒性腹泻病毒(BVDV)抗体滴度明显低于约2岁的奶牛。此外,在0-2个月内接种疫苗的牛的BHV-1滴度明显高于在滴度测量前6个月或更长时间接种疫苗的牛。相比之下,在6个月前接种疫苗的牛的抗BVDV抗体滴度明显高于在1-2个月内接种疫苗的牛。接种疫苗后6个月至1年期间,BVDV抗体滴度相对保持不变。我们的研究表明,BHV-1疾病分离株与多价疫苗的BHV-1之间几乎不存在抗原变异。此外,在那些测试动物中,接种疫苗后6个月时BHV-1抗体滴度相对较低。然而,接种疫苗6个月后,BVDV抗体滴度仍然相对较高。